Skip to main content

Dossier

Guidelines

Wir blicken in das Regelwerk der chirurgischen Zunft und stellen Neuerungen vor.

Guidelines

Early major fracture care in polytrauma – priorities in the context of concomitant injuries

Musculoskeletal injuries are common in polytraumatized patients, and determining the right treatment strategy and timing is crucial for their outcomes. Recently, several fracture fixation strategies like Safe Definitive Surgery (SDS), Early Appropriate Care (EAC), and Prompt Individualized and Safe Management (PRISM) have emerged, but they often vary regionally and are controversial. All these approaches aim to optimize surgical timing based on patient physiology and concomitant injuries.

Early major fracture care in polytrauma – priorities in the context of concomitant injuries
Guidelines

Guidelines Inguinalhernie

Die internationale Konsensus-Guideline zur Behandlung von Inguinalhernien erschien erstmals 20181. Im Juli 2023 erschien das erste Update der Leitlinie, die von allen kontinentalen Herniengesellschaften, der Endo Hernia Society und der European Society for Endoscopic Surgery anerkannt wurde2

Guidelines

The updated S3 guideline on the treatment of patients with severe/multiple injuries

The new German S3 guideline on polytrauma treatment was published in December 20221. The updated guideline entails 332 recommendations, including 139 amendments and led to exciting discussions regarding implementation in local and regional protocols. As co-authors of the 3rd revision of the guideline, we report on the development, content and highlight some novelties of the evidence- and consensus-based S3-guidelines.

Guidelines

Guidelines Ösophaguskarzinom

Die erste Version der S3-Leitlinie zum Ösophaguskarzinom ist 2015 erschienen und liegt nun in neuer Fassung vor. Wir haben die wesentlichen Neuerungen zusammengefasst.

Guidelines

European evidence-based guidelines on pancreatic cystic neoplasms

The term pancreatic cystic neoplasms (PCN) summarizes a heterogenous group of pancreatic cysts such as intraductal papillary mucinous cystic neoplasms (IPMN), mucinous cystic neoplasm (MCN) and serous cystic neoplasm (SCN). They each show distinct biological behaviour with different risk of progression and risk for malignant transformation.

To make this website run properly and to improve your experience, we use cookies. For more detailed information, please check our Cookie Policy.

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.